NEW YORK (Reuters Health) – New research suggests concerns over the concurrent use of bedaquiline and delamanid in patients with drug-resistant tuberculosis were unwarranted. “Prior
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok